logo
West Virginia parent sues seeking religious exemption from required school vaccinations

West Virginia parent sues seeking religious exemption from required school vaccinations

CBS News25-06-2025
A West Virginia woman filed a lawsuit Tuesday seeking a religious exemption from required school vaccinations for her young child.
Miranda Guzman alleges that the state's vaccine mandate violates a 2023 West Virginia law that stipulates the government would not be able to "substantially burden" someone's constitutional right to freedom of religion unless doing so "is essential to further a compelling governmental interest." Guzman sued the state and local boards of education and the county schools superintendent in Raleigh County Circuit Court.
West Virginia was among just a handful of states that granted only medical exemptions from school vaccinations when Republican Gov. Patrick Morrisey issued an executive order in January allowing religious exemptions. However, the state Board of Education voted this month to direct public schools to ignore the executive order and instead follow long-standing school vaccine requirements that are laid out in state law.
Also, two groups have sued over the governor's order, saying the Legislature, not the governor, has the authority to make such decisions.
Guzman obtained a religious exemption to the vaccine mandate from the state health department and enrolled her child in elementary school for the 2025-26 school year. But on June 17, Guzman received an email from the Raleigh County school superintendent rescinding the certificate, according to the lawsuit.
Guzman's attorneys said "the straightforward legal issue" in the lawsuit is whether enforcement of the state vaccine mandate violates the 2023 Equal Protection for Religion Act.
West Virginia Board of Education spokesperson Christy Day referred to a June 12 statement from the board that its intent is to "do what is best" for public school students, educators and school service personnel. "This includes taking the important steps of protecting the school community from the real risk of exposure to litigation that could result from not following vaccination laws," the earlier statement said.
A telephone message left with Raleigh County Schools Superintendent Serena Starcher wasn't immediately returned.
West Virginia's school vaccination policy long has been heralded by medical experts as one of the most protective in the country for children. State law requires children to receive vaccines for chickenpox, hepatitis B, measles, meningitis, mumps, diphtheria, polio, rubella, tetanus and whooping cough before starting school.
Morrisey, who is not a party to the lawsuit, held a news conference Tuesday in Beckley in support of Guzman.
"This is not about whether or not about parents should vaccinate their children," Morrisey said. "This is about standing up for religious liberty."
At least 30 states have religious freedom laws, including one signed by Georgia's governor in April. The laws are modeled after the federal Religious Freedom Restoration Act, signed in 1993 by then-President Bill Clinton, which allows federal regulations that interfere with religious beliefs to be challenged.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

An Ohio couple welcomes a baby boy from a nearly 31-year-old frozen embryo
An Ohio couple welcomes a baby boy from a nearly 31-year-old frozen embryo

CBS News

timea minute ago

  • CBS News

An Ohio couple welcomes a baby boy from a nearly 31-year-old frozen embryo

A baby boy born last week to an Ohio couple developed from an embryo that had been frozen for more than 30 years in what is believed to be the longest storage time before a birth. In what's known as embryo adoption, Lindsey and Tim Pierce used a handful of donated embryos that have been frozen since 1994 in pursuit of having a child after fighting infertility for years. Their son was born Saturday from an embryo that had been in storage for 11,148 days, which the Pierces' doctor says sets a record. It's a concept that has been around since the 1990s but is gaining traction as some fertility clinics and advocates, often Christian-centered, oppose discarding leftover embryos because of their belief that life begins at or around conception and that all embryos deserve to be treated like children who need a home. "I felt all along that these three little hopes, these little embryos, deserved to live just like my daughter did," said Linda Archerd, 62, who donated her embryos to the Pierces. Just about 2% of births in the U.S. are the result of in vitro fertilization, and an even smaller fraction involve donated embryos. However, medical experts estimate about 1.5 million frozen embryos are currently being stored throughout the country, with many of those in limbo as parents wrestle with what to do with their leftover embryos created in IVF labs. Further complicating the topic is a 2024 Alabama Supreme Court decision that said that frozen embryos have the legal status of children. State leaders have since devised a temporary solution shielding clinics from liability stemming from that ruling, though questions linger about remaining embryos. Archerd says she turned to IVF in 1994. Back then, the ability to freeze, thaw and transfer embryos was making key progress and opening the door for hopeful parents to create more embryos and increase their chances of a successful transfer. She wound up with four embryos and initially hoped to use them all. But after the birth of her daughter, Archerd and her husband divorced, disrupting her timeline for having more children. As the years turned into decades, Archerd said she was wracked with guilt about what to do with the embryos as storage fees continued to rise. Eventually, she found Snowflakes, a division of Nightlight Christian Adoptions, which offers open adoptions to donors from people like Archerd. She was also able to set preferences for what families would adopt her embryos. "I wanted to be a part of this baby's life," she said. "And I wanted to know the adopting parents." The process was tricky, requiring Archerd to contact her initial fertility doctor in Oregon and dig through paper records to get the proper documentation for the donation. The embryos then had to be shipped from Oregon to the Pierces' doctor in Tennessee. The clinic, Rejoice Fertility in Knoxville, refuses to discard frozen embryos and has become known for handling embryos stored in outdated and older containers. Of the three donated embryos the Pierces received from Archerd, one didn't make the thaw. Two were transferred to Lindsey Pierce's womb, but just one successfully implanted. According to Dr. John David Gordon, the transfer of the nearly 31-year-old embryo marks the longest-frozen embryo to result in a live birth. He would know: Gordon says his clinic assisted in the previous record, when Lydia and Timothy Ridgeway were born from embryos frozen for 30 years, or 10,905 days. "I think that these stories catch the imagination," Gordon said. "But I think they also provide a little bit of a cautionary tale to say: Why are these embryos sitting in storage? You know, why do we have this problem?" In a statement, Lindsey and Tim Pierce said the clinic's support was just what they needed. "We didn't go into this thinking about records — we just wanted to have a baby," Lindsey Pierce said. For Archerd, the donation process has been an emotional roller coaster. Relief that her embryos finally found a home, sadness it couldn't be with her and a little anxiety about what the future holds next, with possibly meeting the Pierces and the baby in person. "I'm hoping that they're going to send pictures," she said, noting that the parents have already sent several after the birth. "I'd love to meet them some day. That would be a dream come true to meet — meet them and the baby." ___ This story has corrected the first name of Lindsey Pierce in the second paragraph.

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

Yahoo

timean hour ago

  • Yahoo

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified non-responders up to 5 months earlier than standard methods Study shows Guardant Reveal's promise for confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer PALO ALTO, Calif., July 29, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, published today in Cancer Research Communications, a journal of the American Association for Cancer Research, found that Guardant Reveal successfully detected responses to immunotherapy across multiple solid tumor types in advanced stage cancer patients and identified non-responders more than three months—and in some cases nearly five months—before disease progression was visible by standard methods. Approximately 30% of patients with advanced-stage cancer receive immunotherapy treatment, with varying degree and duration of response. This study analyzed a large cohort of more than 500 patients with various advanced solid tumors, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers, receiving immunotherapy in a real-world setting to assess if blood-based monitoring could predict response accurately and faster than standard of care methods. The strong association found between long-term patient outcomes and changes in tumor fraction as measured with the tissue-free, methylation-based Guardant Reveal supports the use of blood-based monitoring to help predict treatment response and improve decision-making in cancer care. "Precise serial monitoring at the molecular level provides real value to oncologists and to patients using immunotherapy," said Craig Eagle, M.D., Chief Medical Officer at Guardant Health. "This study shows that Guardant Reveal has the potential to revolutionize how oncologists assess patient response, identifying earlier insights that can empower them to make informed decisions faster and improve patient outcome and quality of care." "Our RADIOHEAD study of Guardant Reveal in advanced stage cancers provides patients with a new caliber of precision monitoring in order to create better patient outcomes," said Tarak Mody, PhD, Chief Business Officer at PICI. "These findings exemplify PICI's commitment to forging mission-driven partnerships to bring cutting-edge technology into clinical practice, accelerate discoveries, and advance the development of curative immune therapies for patients." Key study findings include: Improved patient outcomes associated with any reduction in tumor fraction 75% lower risk of progression in patients with ≥80% decrease in tumor fraction Disease progression identified up to 5 months prior to standard of care methods The full manuscript in Cancer Research Communications is available here. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. About RADIOHEAD The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program is a pan-tumor, prospective cohort study of 1,070 immunotherapy-naïve patients receiving standard-of-care immune checkpoint inhibitor regimens. Conducted across 49 U.S. community oncology clinics, the study includes over 3,700 longitudinal blood samples collected at pretreatment, early on-treatment, and immune-related adverse event timepoints, with a focus on major immuno-oncology indications such as non-small cell lung cancer (~1,400 samples) and malignant melanoma (~500 samples). Multi-omic profiling (including circulating tumor DNA analysis, whole-exome sequencing, transcriptomics, high-dimensional immune profiling, and serum proteomics) is paired with detailed clinical and demographic data to enable deep translational insights. This comprehensive dataset provides a unique opportunity to uncover mechanisms of response, resistance, and toxicity, and to apply machine learning approaches to explore immune and disease pathways. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Meaghan Smithpress@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store